Neutropenia as a predictor of the effect of trifluridine/tipiracil in patients with advance colorectal carcinoma
2017
Abstract
Trifluridine/tipiracil is a new oral agent combining trifluridine (TFT) with the thymidine phosphorylase inhibitor tipiracil (TPI). Anti-tumour activity of trifluridine/tipiracil in patients with colorectal carcinoma refractory to other systemic therapy has been shown in the randomised, placebo-controlled phase III study RECOURSE, though treatment benefit was found only for some of the patients.
This explains why the search for predictive factors for therapeutic effect of trifluridine/tipiracil continues. In the RECOURSE study occurrence of neutropenia in any cycle was associated with higher median of overall survival as well as of progression-free survival.
Similar results were recorded in other studies investigating this drug as well.